Splenic imaging with ultrasmall superparamagnetic iron oxide ferumoxtran-10 (AMI-7227): Preliminary observations

Journal of Computer Assisted Tomography

Volumn 25, Issue 5, 2001, Pages 770-776

  Harisinghani, Mukesh G ^a,k   Saini, Sanjay ^a   Weissleder, Ralph ^a   Rubin, Daniel ^b   DeLange, Eduard ^c   Harms, Steve ^d   Weinreb, Jeff ^e   Small, William ^f   Sukerkar, Arun ^g   Brown, Jeff J ^h   Zelch, James ⁱ   Lucas, Maria ^j   Morris, Marie ^j   Hahn, Peter F ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Good Samaritan Hospital San Jose   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^d UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^f EMORY UNIVERSITY HOSPITAL   (United States)

^g ADVOCATE ILLINOIS MASONIC MEDICAL CENTER   (United States)

^h WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Regional MRI of Mentor   (United States)

^j Advanced Magnetics Inc ^*  (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

Contrast agents; Ferumoxtran 10; Magnetic resonance imaging; Spleen

Indexed keywords

IMAGE ENHANCEMENT; IRON OXIDES; SUPERPARAMAGNETISM; TISSUE;

CONTRAST AGENT; FERUMOXTRAN-10; LESION DETECTION; LONG CIRCULATING; MANAGEMENT IS; MR CONTRAST AGENTS; PATIENT MANAGEMENT; SPLEEN; T1 RELAXATION; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

MAGNETIC RESONANCE IMAGING;

AMI 7227; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; HEMANGIOMA; HUMAN; IMAGE QUALITY; LYMPHOMA; MALE; METASTASIS; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SPLEEN CANCER; SPLEEN CYST; SPLEEN INFARCTION;

EID: 0034830986     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004728-200109000-00017     Document Type: Article

References (31)

1. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: Ferumoxides, ferumoxtran, ferumoxsil
2. Liver. II: Iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review
3. Clinical evaluation of ultrasmall superparamagnetic iron oxide particles for liver imaging
4. Superparamagnetic agents in magnetic resonance imaging: Physicochemical characteristics and clinical applications. A review
5. Phase I clinical evaluation of a new iron oxide MR contrast agent
6. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: Initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227)
7. Ring enhancement in ultrasmall superparamagnetic iron oxide MR imaging: A potential new sign for characterization of liver lesions
8. Differentiation of liver hemangiomas from metastases and hepatocellular carcinoma at MR imaging enhanced with blood- pool contrast agent code 7227
9. MRI in focal liver disease: A comparison of small and ultra-small superparamagnetic iron oxide as hepatic contrast agents
10. Ultrasmall super-paramagnetic iron oxide: Characterization of a new class of contrast agents for MR imaging
11. Dynamic contrast-enhanced magnetic resonance imaging in a model of splenic metastasis
12. Gadolinium-enhanced MR imaging of the spleen: Artifacts and potential pitfalls
13. MR imaging of acquired abnormalities of the spleen
14. Dynamic gadolinium-enhanced MR imaging of the spleen: Normal enhancement patterns and evaluation of splenic lesions
15. MR imaging of focal splenic tumors
16. MRI of the spleen: Ferrite enhanced detection of splenic metastases
17. Superparamagnetic iron oxide: Enhanced detection of focal splenic tumors with MR imaging
18. Iron oxide nanoparticles for use as an MRI contrast agent: Pharmacokinetics and metabolism
19. Liver-specific MR imaging contrast agents
20. Investigation of mechanisms influencing the accumulation of ultrasmall superparamagnetic iron oxide particles in lymph nodes
21. MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agent
22. Comparison of ultrasmall particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis
23. MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: Radiographic-pathologic correlation
24. Ultrasmall super-paramagnetic iron oxide: An intravenous contrast agent for assessing lymph nodes with MR imaging
25. Ring enhancement in ultrasmall superparamagnetic iron oxide MR imaging: A potential new sign for characterization of liver lesions
26. MR imaging of focal splenic tumors
27. Spleen: Dynamic enhancement patterns on gradient-echo MR images enhanced with gadopentetate dimeglumine
28. Interventional radiology of the spleen
29. Contrast-enhanced MR imaging of liver and spleen: First experience in humans with a new superparamagnetic iron oxide
30. Iron oxide enhanced MR imaging of the liver and spleen: Review of the first five years